Intraoperative parecoxib attenuated systemic inflammatory response associated with CPB during cardiac surgery and lowered the biochemical markers of myocardial injury.
This risk score can stratify patients by risk for developing postoperative respiratory failure after major cardiac surgery, which may help in the development of preventive measures.
